Evaluating time to withdrawal of anti-cancer drug indications that received FDA’s accelerated approval

Journal Article Accepted manuscript Evaluating time to withdrawal of anti-Cancer drug indications that received FDA's accelerated approval Get access Hayase Hakariya, Hayase Hakariya Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen, 72076, GermanyInstitute for Pharmaceutical and Social Health Sciences, Japan To whom correspondence may be addressed. Hayase Hakariya, Ph.D., Interfaculty Institute of Biochemistry, University of Tuebingen, 72076 Tuebingen, Germany, TEL: +49 7071 29 75377. Email: hayase.hakariya@uni-tuebingen.de, haya.pha3@gmail.com (H.H.) https://orcid.org/0000-0002-9121-4551 Search for other works by this author on: Oxford Academic PubMed Google Scholar Akihiko Ozaki, Akihiko Ozaki Department of Breast and Thyroid Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, 972-8322, Japan https://orcid.org/0000-0003-4415-9657 Search for other works by this author on: Oxford Academic PubMed Google Scholar Shai Mulinari, Shai Mulinari Department of Sociology, Lund University, Lund, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar Frank Moriarty, Frank Moriarty School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin, Ireland https://orcid.org/0000-0001-9838-3625 Search for other works by this author on: Oxford Academic PubMed Google Scholar Tetsuya Tanimoto Tetsuya Tanimoto Navitas Clinic, Tokyo, 190-0023, Japan https://orcid.org/0000-0002-9818-8587 Search for other works by this author on: Oxford Academic PubMed Google Scholar QJM: An International Journal of Medicine, hcae115, https://doi.org/10.1093/qjmed/hcae115 Published: 12 June 2024 Article history Received: 04 June 2024 Published: 12 June 2024